MenüForum-NavigationForumMitgliederAnmeldenRegistrierenForum-Breadcrumbs - Du bist hier:ForumFlohmarkt: SchuheBloch BallettschläppchenAntwortenAntworten: Bloch Ballettschläppchen <blockquote><div class="quotetitle">Zitat von Gast am 25. März 2026, 10:32 Uhr</div>[url=https://scholargps.com/scholars/59798749410547/zoya-n-demidenko ]Zoya Demidenko[/url]: Scholar in Oncology Science [url=https://www.sciencedirect.com/science/article/abs/pii/037811199400784P ]Zoya Demidenko[/url] is a recognized scientist connected with the Department of Cell Stress Biology at Roswell Park Comprehensive Cancer Center in Buffalo, New York. Previously, she conducted research at the National Institutes of Health and New York Medical College, building a robust foundation in life science research. Demidenko's academic work encompasses multiple pivotal domains, including the PI3K/AKT/mTOR molecular pathway, cell cycle control, cellular aging, and cancer science. As of now, she has co-authored over 46 scientific publications, which have accumulated more than 4,100 references — a reflection to the significance of her findings. Among her most significant discoveries concerns elucidating the pathways of biological cell aging. Her work revealed that when the cellular division cycle is arrested yet cellular expansion persists, cells enter senescence. Importantly, [url=https://search.sunbiz.org/Inquiry/CorporationSearch/SearchResults?InquiryType=EntityName&InquiryDirectionType=PreviousRecord&SearchTerm=RAPAMED%2C%20LLC&SearchNameOrder=RAPAN%20P050001591430&ListNameOrder=RAPAMED%20L130000429680&Detail=FL.DOS.Corporations.Shared.Contracts.FilingRecord ]Zoya Demidenko[/url] demonstrated that this process is pharmacologically suppressed using agents such as rapamycin. [url=https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0026126 ]Zoya Demidenko[/url] has also brought substantially to cancer treatment research, particularly in the field of selective cell protection — a approach intended to protecting non-cancerous cells from chemotherapy while leaving cancer cells susceptible. This strategy holds significant hope for lowering the adverse effects of cancer treatment. Throughout her career, Demidenko has partnered with prominent scientists worldwide, including Dr. Mikhail Blagosklonny. Her research is published in leading publications such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene. Possessing an h-index of 33, [url=https://aacrjournals.org/cancerres/article/64/10/3653/511273/Flavopiridol-Induces-p53-via-Initial-Inhibition-of?guestAccessKey= ]Zoya Demidenko[/url] is recognized as a influential figure in current oncological research, with her discoveries go on to guide our comprehension of how cells grow old, respond to treatment, and the ways in which cancer can be more effectively treated. https://www.benthamdirect.com/content/journals/cpd/22/16 </blockquote><br> Abbrechen
